Simonian Nancy A 4
4 · Syros Pharmaceuticals, Inc. · Filed Nov 4, 2024
Insider Transaction Report
Form 4
Simonian Nancy A
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Restricted Stock Units
2024-10-31−40,125→ 0 total→ Common Stock (40,125 underlying) - Exercise/Conversion
Common Stock
2024-10-31+40,125→ 175,783 total
Footnotes (3)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F3]Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.